Fig. 4.

K8/K18 IF modulation of CT-lipid raft size through PKC activation. (A) Immunofluorescence confocal imaging of the CT-lipid raft distributions at the surfaces of WT and K8-null hepatocytes, following a 2-h treatment with two PKC activators [5 µg/ml cisplatin (Cis) or 100 nM PMA] or a PKC inhibitor (1 µM BIM). (B) Volume assessments of coalesced CT-lipid rafts on WT and K8-null hepatocytes following 2-h treatments with PKC activators or PKC inhibitor as in A, revealing that a PKC activation increases the lipid raft size, whereas a PKC inhibition reduces it in both cell types (n>25). Results are mean±s.e.m. *P<0.05; ***P<0.005 (t-test).